GE Healthcare shows off ‘revolutionising’ imaging technology

GE Healthcare has displayed its latest medical imaging technology that has the potential to “revolutionise effectiveness and cost of patient care”.

At the Society of Nuclear Medicine’s conference in San Diego, the UK-based company said that its nuclear positron emission tomography (PET) and computed tomography helped doctors locate and treat diseases earlier, in addition to ultrasound, magnetic resonance and optical imaging technologies.

It also highlighted new drug diagnostic technologies developed in conjunction with companies such as Roche, Merck and Eli Lilly.

Jean-Luc Vanderheyden, GE Healthcare’s global molecular imaging leader, remarked: “GE Healthcare’s leadership in molecular imaging continues to attract partners from the pharmaceutical industry and academic centers of excellence worldwide, who are interested in enhancing drug development and helping to transform the future of healthcare.”

“With more physicists, biologists, radiochemists and engineers than any other company in the world, we are developing in vitro diagnostic tests, combined with new targeted in vivo molecular imaging agents and sophisticated detection equipment, to provide fresh insight on health and disease management,” he concluded.

GE Healthcare has over 43,000 employees and has locations throughout the UK, including Slough, Worcester, Glasgow, Hatfield and its global headquarters in Chalfont St Giles, Berkshire.

One of the products on show was Imanet, a PET imaging system with the ability to provide information on drug-receptor interactions in biochemical and physiological processes at a molecular level.

© Adfero Ltd